BRCA阳性转移性去势抵抗性前列腺癌患者对标准治疗敏感性的系统综述与Meta分析
该系统综述与Meta分析纳入16项研究、348例BRCA1/2阳性mCRPC患者,评估阿比特龙、恩扎卢胺和多西他赛一线治疗的PSA50反应率及PFS、OS。PSA50反应率分别为52%、64%和55%;恩扎卢胺较阿比特龙有PFS获益(HR 0.47),但无OS获益(HR 1.41)。
要点
- BRCA1/2阳性mCRPC一线阿比特龙、恩扎卢胺和多西他赛的PSA50反应率分别为52%、64%和55%。
- 恩扎卢胺较阿比特龙有PFS获益(HR 0.47,95%CI 0.26-0.83,P=0.010),但无OS获益(HR 1.41,95%CI 0.82-2.42,P=0.210)。
- 基于PSA50和PFS分析,BRCA阳性mCRPC患者可能对恩扎卢胺反应更好,但需分子标志物驱动的干预性研究直接比较这些药物。
核心结论
- PSA50分析显示三种一线治疗对BRCA1/2阳性mCRPC均有治疗效果;基于PSA50和PFS分析,BRCA阳性mCRPC患者可能对恩扎卢胺反应更好。
- 作者认为,分子标志物驱动的干预性研究直接比较这些药物对提供更高等级证据至关重要。
研究设计与样本
- 因无干预性试验,该系统综述与Meta分析采用比例数据和个体患者数据合成BRCA1/2阳性mCRPC患者数据。
- 共纳入16项符合条件的研究,包含348例BRCA1/2阳性mCRPC患者。
- PSA50评估采用事件率合并及95%CI,PFS和OS分析采用个体患者数据随机效应Cox回归计算。
主要发现
- 一线治疗中,阿比特龙、恩扎卢胺和多西他赛的PSA50反应率分别为52%(CI: 25-79%)、64%(CI: 43-80%)和55%(CI: 36-73%)。
- 个体患者数据分析显示,恩扎卢胺较阿比特龙治疗患者有PFS获益(HR: 0.47,CI: 0.26-0.83,p = 0.010),但无OS获益(HR: 1.41,CI: 0.82-2.42,p = 0.210)。
关键数值与推荐
- PSA50反应率:阿比特龙52%(CI: 25-79%),恩扎卢胺64%(CI: 43-80%),多西他赛55%(CI: 36-73%)。
- 恩扎卢胺 vs 阿比特龙:PFS的HR为0.47(CI: 0.26-0.83,p = 0.010);OS的HR为1.41(CI: 0.82-2.42,p = 0.210)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation-positive metastatic castration-resistant PCa (mCRPC) patients following prior treatment with abiraterone, enzalutamide or docetaxel. However, the question of which of these standard treatments is the most effective for BRCA1/2 positive mCRPC patients remains to be answered. The aim of this meta-analysis was to assess the efficacy of abiraterone, enzalutamide and docetaxel in BRCA1/2 mutation-positive mCRPC patients in terms of PSA-response (PSA50), progression-free survival (PFS) and overall survival (OS). METHODS: As no interventional trials are available on this topic, we performed the data synthesis of BRCA1/2 positive mCRPC patients by using both proportional and individual patient data. For PSA50 evaluation, we pooled event rates with 95% confidence intervals (CI), while for time-to-event (PFS, OS) analyses we used individual patient data with random effect Cox regression calculations. RESULTS: Our meta-analysis included 16 eligible studies with 348 BRCA1/2 positive mCRPC patients. In the first treatment line, response rates for abiraterone, enzalutamide and docetaxel were 52% (CI: 25-79%), 64% (CI: 43-80%) and 55% (CI: 36-73%), respectively. Analyses of individual patient data revealed a PFS (HR: 0.47, CI: 0.26-0.83, p = 0.010) but no OS (HR: 1.41, CI: 0.82-2.42, p = 0.210) benefit for enzalutamide compared to abiraterone-treated patients. CONCLUSIONS: Our PSA50 analyses revealed that all the three first-line treatments have therapeutic effect in BRCA1/2 positive mCRPC; although, based on the results of PSA50 and PFS analyses, BRCA positive mCRPC patients might better respond to enzalutamide treatment. However, molecular marker-driven interventional studies directly comparing these agents are crucial for providing higher-level evidence.
引用
- Fazekas T, Széles ÁD, Teutsch B, et al. Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 36509931. doi:10.1038/s41391-022-00626-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。